- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02512458
Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer (CABA-BONE)
A Study of Cabazitaxel Treatment in Castration Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Microenvironment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, interventional study to explore the effect of Cabazitaxel on survival pathways and androgen signaling in the tumor microenvironment (bone marrow) of patients with castration resistant metastatic prostate cancer.
A total of 30 evaluable patients are needed. An estimated 50% chance of failure to harvest evaluable bone marrow biopsy or aspirate is anticipated based on investigators prior experience. Thus a total of 60 patients will be accrued in the study. This will provide the investigators an 80% power to detect an effect size of at least 0.82, using a two-sided paired t-test and at a 0.05 significance level.The changes in androgen signaling (androgen receptor expression and other survival pathway markers, between baseline and 9 weeks will be assessed by paired t-test and Wilcoxon signed-rank test. The association between serum Prostate-Specific Androgen (PSA) and bone marrow androgen signaling level will be evaluated using scatter plot and spearman's correlation coefficient. Similar methods will be used to explore the association between circulating androgens and those in the bone marrow.
Biomarker data will also be summarized and compared between baseline and after treatment using paired t-test or Wilcoxon signed-rank test.
ECOG changes from baseline will be provided for each treatment period. All Adverse Events (AE) will be graded using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) classification, version 4.3.
Summary tables of Adverse Events (AE)s, Treatment Emergent Adverse Event(TEAE), Serious Adverse Events (SAE)s and withdrawals for adverse events will be provided by treatment period. Adverse events will be summarized by worst severity grade AEs.
All registered subjects who take at least 1 dose of agent will be included in the safety analyses. Adverse events will be summarized by worst severity grade. AEs, as well as treatment-emergent AEs, will be summarized by system organ class, and preferred term. Investigational Medicinal Products (IMP) -related adverse events, adverse events leading to death or to discontinuation from treatment, events classified as NCI-CTCAE v4 Grade 3 or Grade 4 (or moderate/severe if other rating scale is used), (IMP)-related events, and serious adverse events will be summarized separately.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 11528
- General Hospital of Athens "Alexandra", Unit of Medical Oncology, Dept of Clinical Therapeutics
-
Athens, Greece, 14564
- Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology
-
Ioannina, Greece, 45110
- Ioannina University Hospital, Dept of Medical Oncology
-
Thessaloniki, Greece, 56429
- Papageorgiou General Hospital, Dept of Medical Oncology
-
-
Maroussi
-
Athens, Maroussi, Greece, 15125
- Athens Medical Center, Dept of Medical Oncology
-
-
Thessaloniki
-
Thessaloníki, Thessaloniki, Greece, 54645
- EUROMEDICA General Clinic of Thessaloniki
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male patients older than 18 years
- Histologically proven adenocarcinoma of the prostate
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Serum testosterone levels < 50ng/ml (1.7 nmol/L)
- Ongoing gonadal androgen deprivation therapy with Luteinizing Hormone-Releasing Hormone (LHRH) analogues or orchiectomy. Patients, who have not had an orchiectomy, must be maintained on effective LHRH analogue therapy for the duration of the trial
- Progression of disease despite androgen ablation - Either documented osseous or soft tissue metastatic disease progression or by PSA criteria progression
- Presence of bone metastases
- Off diethylstilbestrol (DES) or steroids treatment for ≥ 4 weeks and for antiandrogens > 4 weeks.
- No prior treatment with cabazitaxel
- Able to comply with study requirements
- Written information delivered to the patient. Patient must be willing and able to comply with protocol requirements. All patients must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must also have signed an authorization for the release of their protected health information.
Exclusion Criteria:
- Histologic variants in the primary tumor (histologic variants other than adenocarcinoma)
- Concurrent therapy with other therapeutic or hormonal agent, including androgen receptor antagonists (bicalutamide, flutamide, nilutamide, enzalutamide), any dose of megestrol acetate (Megace), ketoconazole, abiraterone acetate, finasteride (Proscar), dutasteride (Avodart) any herbal product known to decrease PSA levels (e.g., Saw Palmetto and PC-SPES),
- Active infection or intercurrent illnesses that are not controlled
- Prior radiation therapy completed < 4 weeks prior to enrolment
- Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
- Structurally unstable bone lesions suggesting impending fracture
- Any "currently active" second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next 3 months
- Active psychiatric illnesses/social situations that would limit compliance with protocol requirements.
- Active or uncontrolled autoimmune disease that may require corticosteroid therapy during study.
- Severely compromised immunological state, including being positive for the human immunodeficiency virus (HIV)
- Known acute or chronic hepatitis B or C
- Other investigational therapies (targeted or vaccine) will require a 4 week washout period before treatment initiation
- Ιnitiation of bisphosphonate or denosumab therapy within 4 weeks prior to first dose of study drug. Patients on stable doses of bisphosphonates or denosumab that show subsequent tumor progression may continue on this medication; however, patients are discouraged to initiate bisphosphonate therapy during the study.
- Patients receiving an investigational drug within 4 weeks prior to enrolment
- History of severe hypersensitivity reaction (grade ≥3) to polysorbate 80 containing drugs
- Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus)
- Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments)
- Inadequate organ or bone marrow function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cabazitaxel
Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Molecular effects of treatment with Cabazitaxel on the tumor microenvironment
Time Frame: On week 9 and on week 36
|
To explore molecular effects of treatment with Cabazitaxel on the tumor microenvironment of patients with mCRPC in correlation with measures of outcome (ie clinical benefit, Prostate-Specific Androgen (PSA) decline, radiographic response, time to treatment discontinuation), in an effort to identify predictors of response or resistance to therapy.
|
On week 9 and on week 36
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Eastern Cooperative Oncology Group (ECOG) performance status
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
PSA response
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
Radiological progression-free survival according to Prostate Cancer Working Group 2 (PCWG2)
Time Frame: Up to 30 weeks or until Disease Progression
|
Up to 30 weeks or until Disease Progression
|
Pain status using a numerical rating scale from 0 to 10.
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
Time to best clinical benefit (based on pain, analgesic consumption, and performance status)
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
Overall survival
Time Frame: Up to 40 months
|
Up to 40 months
|
Explore the potential association between serum PSA with bone marrow (BM) androgen (testosterone, dehydrotestosterone, androstenedione, cortisol, pregnenolone and progesterone) levels and androgen receptor expression while on Cabazitaxel
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
Prospective collection of BM biopsies and aspirates to measure the effect of Cabazitaxel on markers of bone metabolism(N-terminal Androgen Receptor(AR),C-terminal AR,splice variant presence,NKX3.1,AR coactivator expression,CYP17,p53,Aurora kinase,UBE2C)
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
Correlation between levels of circulating androgens(testosterone, dehydrotestosterone,androstenedione,cortisol,pregnenolone and progesterone)and those in the bone marrow before and during treatment with Cabazitaxel with measures of efficacy
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
Number of participants with Serious and Non-Serious Adverse Events graded according to National Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0
Time Frame: Up to 30 weeks
|
Up to 30 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Eleni Efstathiou, MD,Ass. Prof, Unit of Medical Oncology,Department of Clinical Theraputics,General Hospital of Athens "Alexandra"
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HE 9A/14
- 2014-004485-21 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Metastatic Prostate Cancer
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
Stanford UniversityNational Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate CancerUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedCastration Resistant Prostate Cancer | Prostate Carcinoma Metastatic to the BoneUnited States
-
University of Wisconsin, MadisonProstate Cancer Foundation; Madison Vaccines, IncCompletedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Athenex, Inc.CompletedBone-Metastatic, Castration-Resistant Prostate CancerUnited States
-
Duke UniversityBayerCompletedPharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate CancerBone Metastatic Castration-Resistant Prostate CancerUnited States
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Novartis; Prostate Cancer Clinical Trials ConsortiumCompletedMetastatic Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
Clinical Trials on Cabazitaxel
-
Jeffrey Yachnin M.D., PhD.SanofiCompletedMetastatic Castration Resistant Prostate CancerSweden
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiCompleted
-
Vejle HospitalSanofiTerminated
-
Azienda Socio Sanitaria Territoriale degli Spedali...San Luigi Gonzaga HospitalUnknown
-
Institut für Klinische Krebsforschung IKF GmbH...Completed
-
Gustave Roussy, Cancer Campus, Grand ParisSanofiUnknownNon-seminomatous Germ-cell TumorsFrance
-
Rambam Health Care CampusCompleted
-
University Hospitals Bristol and Weston NHS Foundation...SanofiCompletedPenile NeoplasmUnited Kingdom
-
Brown UniversityTerminated
-
European Organisation for Research and Treatment...SanofiCompletedDedifferentiated LiposarcomaUnited Kingdom, Belgium, France, Italy